9th Circ. Won't Rehear Investor Suit Over Arena's Diet Drug

Law360, New York (January 10, 2017, 6:35 PM EST) -- The Ninth Circuit on Tuesday denied Arena Pharmaceuticals' request for a full panel rehearing of its decision that revived a proposed class action alleging the company lied to shareholders that testing for its new diet drug was going smoothly.

The appellate court refused to touch its October ruling that the pharmaceutical company's mentioning of animal studies in company disclosures obligated it to tell shareholders about the U.S. Food and Drug Administration's prior concerns that the drug, lorcaserin, could cause cancer in humans.

Arena Pharmaceuticals Inc. had beat the shareholders' case in late 2013 after U.S. District Judge Cathy Ann Bencivengo concluded...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!